The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

@article{Nielsen2018TheUO,
  title={The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews},
  author={Suzanne Nielsen and Rada Germanos and Megan Weier and John David Pollard and Louisa Degenhardt and Wayne D. Hall and Nicholas S. Buckley and Michael Farrell},
  journal={Current Neurology and Neuroscience Reports},
  year={2018},
  volume={18},
  pages={1-12}
}
Purpose of ReviewPharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function… 
Cannabinoids for the treatment of spasticity
TLDR
Paediatric studies of spasticity provide low quality evidence and are inadequate to inform clinical practice, and should be considered in the context of the narrow therapeutic index of cannabinoids forSpasticity and adverse effects.
Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations.
  • D. Erku, S. Shrestha, P. Scuffham
  • Medicine
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2021
TLDR
Medicinal cannabis-based products may be cost-effective treatment options for MS spasticity, Dravet syndrome, and neuropathic pain, although the literature is nascent.
Medical Cannabis for Older Patients
TLDR
A pragmatic clinical approach to a rational dialogue with older patients is proposed, highlighting the importance of individual benefit–risk assessment and shared patient–clinician decision making.
Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?
TLDR
Until there is better evidence of effectiveness and safety in paediatric spasticity related to CP, it would be prudent not to use nabiximols to treat this condition, and the burden is placed on advocates of the use of nabixomols in this condition to provide better evidence.
Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
TLDR
Treatment efficacy was associated with baseline dementia severity and dose, but not dementia subtype, age, or sex, and preliminary evidence for the efficacy and tolerability of cannabinoids as treatments for NPS is found.
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence
TLDR
It is difficult to make a recommendation for the use of CBD in chronic pain management, but it is important to note that there are many CBD products currently available as supplements, but these products are non-pharmaceuticals and lack the appropriate clinical studies to support their efficacy claims.
An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine
TLDR
Clinicians are provided with an update of currently available and promising developmental cannabis pharmaceutical derivatives which may stand to greatly benefit patients with otherwise difficult-to-treat chronic conditions.
Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain
TLDR
The current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain is outlined and limits on generalisability of previous findings are discussed.
Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence
TLDR
There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients, and their multimodal action may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity.
A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019
TLDR
The body of evidence for medical cannabis requires more rigorous evaluation before consideration as a treatment option for many conditions, and evidence necessary to inform policy and treatment guidelines is currently insufficient for many condition.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
TLDR
Evidence is found that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms and subjective assessment of symptom relief did often show significant improvement post-treatment.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome.
Role of Cannabinoids in Multiple Sclerosis
TLDR
An increasing amount of evidence is now emerging to confirm anecdotal reports of symptomatic improvement, particularly for muscle stiffness and spasms, neuropathic pain and sleep and bladder disturbance, in patients with MS treated with cannabinoids.
Adverse effects of medical cannabinoids: a systematic review
TLDR
Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events, and high-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
TLDR
Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful.
Cannabinoids in medicine: A review of their therapeutic potential.
TLDR
Cannabinoids present an interesting therapeutic potential as antiemetics, appetite stimulants in debilitating diseases, analgesics, and in the treatment of multiple sclerosis, spinal cord injuries, Tourette's syndrome, epilepsy and glaucoma.
Cannabidiol in Humans—The Quest for Therapeutic Targets
TLDR
Preliminary clinical trials suggest that high-dose oral CBD may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation.
Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials
TLDR
None of the studies reviewed were powered to detect a difference with the treatment of a cannabinoid agonist, therefore, currently no conclusions can be made on the efficacy of cannabinoids in the Treatment of movement disorders.
Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
TLDR
Treatment efficacy was associated with baseline dementia severity and dose, but not dementia subtype, age, or sex, and preliminary evidence for the efficacy and tolerability of cannabinoids as treatments for NPS is found.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
TLDR
A systematic review of medical marijuana to address treatment of symptoms of multiple sclerosis, epilepsy, and movement disorders found oral cannabinoids are of unknown efficacy in non–chorea-related symptoms of Huntington disease, Tourette syndrome, cervical dystonia, and epilepsy.
...
1
2
3
4
5
...